The paradigm of treatment for HER2 (+) breast cancer has evolved from a cytotoxic chemotherapy plus single antibody combination to a dual-targeted strategy and antibody-drug conjugates [22,23]. The gene discussed is ERBB2; the disease is breast carcinoma.